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Background: Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment.
Case presentation: We report here on the case of a patient presenting with hypersensitivity pneumonitis while
being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor.
Conclusion: Side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored
carefully to allow for prompt management.
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The incidence of neuroendocrine tumours is increasing.
They are often diagnosed at an advanced stage, with
conventional chemotherapy treatments having a limited
effect. Therefore, novel therapeutic agents are currently
being investigated, notably everolimus, a mammalian
target of rapamycin (mTOR) inhibitor.
Neuroendocrine tumours have recently been shown to
display a genetic anomaly that may lead to an activation
of the mTOR pathway [1]. The mTOR kinase protein,
however, is a central regulator of cellular proliferation,
growth, angiogenesis, and metabolism [2]. The predomin-
ant side effects of everolimus therapy include mucositis
and buccal ulcers, but less commonly, hypersensitivity
pneumonitis. We report here on the case of a patient pre-
senting with hypersensitivity pneumonitis while being
treated with everolimus.
Case presentation
A 52-year-old man was followed up in our centre for a
small intestinal neuroendocrine tumour with hepatic
synchronous metastases diagnosed in 2001. The patient* Correspondence: laetitia.dahan@mail.ap-hm.fr
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distribution, and reproduction in any mediuminitially underwent small bowel and hepatic surgery
combined with radiofrequency ablation, the latter being
repeated in 2005 for a recurrence of hepatic metastases.
Due to the progression of the disease, the patient was in-
cluded in the Radiant-2 [3] trial that evaluated the efficacy
of octreotide plus everolimus versus placebo plus octreo-
tide on progression-free survival (PFS); he remained in the
study for a period of 2 years. Following the initial stabilisa-
tion of the hepatic lesions, the patient experienced
disease progression, leading to withdrawal from the study.
Unblinding revealed that the patient was in the placebo
plus octreotide arm.
In February 2010, everolimus therapy was initiated.
Three months later, the first evaluation revealed a partial
response, with a decrease in tumour size by 28% accord-
ing to RECIST (Response Evaluation Criteria In Solid
Tumours) criteria. During the 4th month of treatment,
the patient experienced disabling dyspnoea of grade 2,
without cough. Blood gas analysis showed uncompensated
respiratory alkalosis. On thoracic computed-tomography
(CT) scan, there was a pattern of alveolar condensation
and air bronchogram in the left and right inferior lobes
(Figure 1). Pulmonary function testing revealed a moderate
restrictive syndrome. The bronchoalveolar lavage (BAL)
showed lymphocyte-predominant alveolitis, while bacterial
screening and serology tests of atypical pneumonia wereentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Scan taken at 4 months following the initiation of everolimus therapy during the dyspnoea episode: alveolar condensation of
the right and left inferior lobe with an air bronchogram, predominant on the left-side.
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due to Grade 3 hypersensitivity pneumonitis, which was
likely linked to everolimus therapy. Consequently, the
treatment was interrupted, following which the patient’s
respiratory symptoms returned to normal as did CT im-
ages (Figure 2).
Discussion
Everolimus is currently used in the treatment of a number
of diseases: metastatic renal cancer resistant to sorafenib
or sunitinib, non-small cell lung cancer unresponsive to
anti-epidermal growth factor receptor (EGFR) therapy, as
well as in cardiac or renal transplant patients. In addition,
the drug is undergoing evaluation in metastatic breast
cancer, gastric cancer, hepatocellular carcinoma, and non-
Hodgkin lymphoma.
Two phase III trials assessed the efficacy of everolimus
on PFS. In the Radiant-3 trial [4] conducted on patients
with pancreatic neuroendocrine tumours, everolimus
was associated with a significant 6.4-month increase in
median PFS versus placebo. Median PFS was 11 months
with everolimus plus best supportive care, comparedFigure 2 Control scan at 4 months after everolimus
discontinuation: regression of bilateral parenchymatous lesions.with 4.6 months for placebo plus best supportive care
(hazard ratio = 0.35; 95% Confidence Interval (CI) [0.27-
0.45]). In the Radiant-2 trial [3], the improvement in
PFS in patients with advanced neuroendocrine tumours
just missed statistical significance at the predetermined
level set by the study design, but median overall survival
was higher in the everolimus arm compared with the
placebo arm, 12 vs. 8.6 months (hazard ratio = 0.77, P =
0.026), respectively.
As described in the literature [5], the most frequently re-
ported side-effects of everolimus include infections,
oedematous syndrome, cutaneous reactions (e.g., rash,
itching, and dry skin), gastrointestinal problems (e.g., mu-
cositis, diarrhoea, anorexia, nausea, and vomiting), asthe-
nia, acute renal insufficiency, and pulmonary disease,
including pneumonitis as in the case of our patient. Non-
infectious pneumonitis is a known class effect of rapamy-
cin derivatives. This side-effect was found in 13.5% [5] to
25% [6] of cases in the two major everolimus efficacy trials
(12% in the Radiant-2 trial and 17% in Radiant-3) and was
more commonly Grade 1–2 (10-14% being Grade 1–2
and 2–3% Grade 3–4) [3,4].
Symptoms of pneumonitis include dry cough, dys-
pnoea, hypoxemia, asthenia, fever, and weight loss [7,8],
developing between 34 and 491 days after treatment ini-
tiation [5-8]. On radiographic and CT lung imaging, in-
filtration or opacity of the lower lobes may be observed
[6,9], even in the absence of pulmonary symptoms [5].
The BAL shows lymphocytic alveolitis, with samples
testing negative for infection [7,8]. The development of
this type of pneumonitis appears to be independent from
serum everolimus levels [8]. The physiopathology of
pneumonitis is likely based on the accumulation of colla-
gen in the extracellular matrix, the proliferation and mi-
gration of fibroblasts, and the loss of functional alveolar
gas exchange units [10].
Management depends on the severity of clinical symp-
toms, though the pneumonitis is usually reversible after
dose reduction or treatment discontinuation [5,6,8,11,12].
In cases where the diagnosis is based on radiographic
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mus may be continued at the same dose. In cases of mod-
erate to severe symptoms, everolimus therapy should be
temporarily stopped until pneumonitis has resolved, then
re-instituted at a lower dose. Corticosteroids may also be
administered [5].
Conclusion
These relatively frequent side effects of everolimus
should be familiar to clinicians, including nonspecialists,
and be monitored carefully to allow for prompt manage-
ment. Recommendations for optimal management strat-
egies are necessary.
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